<DOC>
	<DOCNO>NCT00619489</DOCNO>
	<brief_summary>This open-label study provide opportunity participant Ulcerative Colitis ( UC ) previously complete Study C13002 ( NCT01177228 ) , treatment-naïve participant UC Crohn 's Disease ( CD ) receive treatment vedolizumab , determine long term safety vedolizumab patient afflicted disease .</brief_summary>
	<brief_title>Long Term Safety Vedolizumab ( MLN0002 ) Patients With Ulcerative Colitis Crohn 's Disease</brief_title>
	<detailed_description>This phase 2 , multiple-dose , open-label study vedolizumab administer intravenously ( IV ) every 8 week . The study population include treatment-naïve ulcerative colitis ( UC ) Crohn 's Disease ( CD ) participant , well 38 UC participant tolerate vedolizumab well Study C13002 ( NCT01177228 ) . In original study protocol , participant randomize receive vedolizumab dose either 6 mg/kg 10 mg/kg . With implementation Amendment 1 , assign dos vedolizumab decrease 2.0 mg/kg 6.0 mg/kg . To implement dose change , instead randomize participant across dos , roll Study C13002 reassign receive 2.0 mg/kg dose participant enter C13004 naïve treatment receive 6.0 mg/kg dose , start next scheduled dosing day . Also , participant assign 2 mg/kg dose experience flare , receive high 6 mg/kg dose . In result analysis study , participant group accord low dose receive , i.e. , 2.0 mg/kg 6.0 mg/kg vedolizumab .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Confirmed active ulcerative colitis ( UC ) Crohn 's Disease ( CD ) Crohn 's Disease Activity Index ( CDAI ) Score 220 450 participant CD Partial Mayo score 2 7 participant UC Patient appropriate candidate biologic therapy per guideline Uptodate cancer screen No severe systemic disease Patients evidence abscess Agree comply study procedure include contraception Low lymphocyte count History image abnormality , multiple sclerosis ( MS ) , brain tumor neurological illness Active recent serious infection Recent treatment biologic ( i.e. , Remicade ) investigational drug Impending surgery Any participant vedolizumab human antihuman antibody ( HAHA ) titer ≥1:125 previous immediate hypersensitivity reaction shortly vedolizumab infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>